| ARGENX SE EO -,10 |
| Niederlande |
| Gesundheit |
| NL0010832176 / A11602 |
| 1AE (Frankfurt) |
| FRA:1AE, ETR:1AE, 1AE:GR |
| EuroStoxx50 |
| https://www.argenx.com/ |
|
argenx SE is a commercial-stage, global, fully-integrated biopharmaceutical company headquartered in Amsterdam, Netherlands, specializing in the development of differentiated antibody-based therapies for severe autoimmune diseases. The company levera..
>Volltext.. |
| 50649.6 Mio. EUR |
| 46171.93 Mio. EUR |
| 4545.33 Mio. EUR |
| 1337.87 Mio. EUR |
| 1491.92 Mio. EUR |
| 24.14 EUR |
| 41.71 Mio. EUR |
| 3180.33 Mio. EUR |
| 987.23 Mio. EUR |
| 3.29 |
| 59.81% |
| 24.69% |
| - |
| - |
| - |
| - |
| ARGENX, ARGEN-X, ARGEN X |
| 08.10.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|